secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001654954-24-003775
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics reports FY2023 net loss $7.7M; Phase 3 LEVEL trial underway
------------------------------------------------------------------------------

- Cash $9.8M at Dec 31, 2023; Feb 2024 public offering netted ~$8.0M.
- Net loss $7.7M (FY2023) vs $11.0M (FY2022); R&D expense down to $3.2M.
- First patient enrolled in Phase 3 LEVEL study for TNX-103 (oral levosimendan) in PH-HFpEF.
- Secured global commercial and IP rights for levosimendan in PH-HFpEF; topline data expected H2 2025.
- KOL event 'LEVEL Setting' scheduled for April 18, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424003775/0001654954-24-003775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424003775/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-003775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer